|
1 Indications And Usage Imatinib Mesylate Tablets Are A Kinase Inhibitor Indicated For The Treatment Of: Newly Diagnosed Adult And Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (ph+ Cml) In Chronic Phase ( 1.1 ) Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (ph+ Cml) In Blast Crisis (bc), Accelerated Phase (ap), Or In Chronic Phase (cp) After Failure Of Interferon-Alpha Therapy ( 1.2 ) Adult Patients With Relapsed Or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ph+ All) ( 1.3 ) Adult Patients With Myelodysplastic/myeloproliferative Diseases (mds/mpd) Associated With Pdgfr (platelet-Derived Growth Factor Receptor) Gene Re-Arrangements As Determined With An Fda-Approved Test ( 1.5 ) Adult Patients With Aggressive Systemic Mastocytosis (asm) Without The D816v C-Kit Mutation As Determined With An Fda-Approved Test Or With C-Kit Mutational Status Unknown ( 1.6 ) Adult Patients With Hypereosinophilic Syndrome (hes) And/or Chronic Eosinophilic Leukemia (cel) Who Have The Fip1l1-Pdgfrα Fusion Kinase (mutational Analysis Or Fish Demonstration Of Chic2 Allele Deletion) And For Patients With Hes And/or Cel Who Are Fip1l1-Pdgfrα Fusion Kinase Negative Or Unknown ( 1.7 ) Adult Patients With Unresectable, Recurrent And/or Metastatic Dermatofibrosarcoma Protuberans (dfsp) ( 1.8 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (ph+ Cml) Newly Diagnosed Adult And Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (ph+ Cml) In Chronic Phase. 1.2 Ph+ Cml In Blast Crisis (bc), Accelerated Phase (ap) Or Chronic Phase (cp) After Interferon-Alpha (ifn) Therapy Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia In Blast Crisis, Accelerated Phase, Or In Chronic Phase After Failure Of Interferon-Alpha Therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (all) Adult Patients With Relapsed Or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ph+ All). 1.5 Myelodysplastic/myeloproliferative Diseases (mds/mpd) Adult Patients With Myelodysplastic/myeloproliferative Diseases Associated With Pdgfr (platelet-Derived Growth Factor Receptor) Gene Re-Arrangements As Determined With An Fda-Approved Test [see Dosage And Administration (2.6) ] . 1.6 Aggressive Systemic Mastocytosis (asm) Adult Patients With Aggressive Systemic Mastocytosis Without The D816v C-Kit Mutation As Determined With An Fda-Approved Test [see Dosage And Administration (2.7) ] Or With C-Kit Mutational Status Unknown. 1.7 Hypereosinophilic Syndrome (hes) And/or Chronic Eosinophilic Leukemia (cel) Adult Patients With Hypereosinophilic Syndrome And/or Chronic Eosinophilic Leukemia Who Have The Fip1l1-Pdgfrα Fusion Kinase (mutational Analysis Or Fish Demonstration Of Chic2 Allele Deletion) And For Patients With Hes And/or Cel Who Are Fip1l1-Pdgfrα Fusion Kinase Negative Or Unknown. 1.8 Dermatofibrosarcoma Protuberans (dfsp) Adult Patients With Unresectable, Recurrent And/or Metastatic Dermatofibrosarcoma Protuberans.
|